The World Health Organization has issued its first-ever global guidelines endorsing GLP-1 medications for obesity treatment, potentially opening the floodgates to massive healthcare spending increases while acknowledging “limited data” on their long-term safety.
Story Snapshot
- WHO releases first global guidelines endorsing GLP-1s for obesity despite limited long-term safety data
- Global obesity costs projected to reach $3 trillion by 2030, driving push for expensive pharmaceutical solutions
- One in eight American adults is already taking GLP-1 medications, with the market projected to hit $126 billion by 2029
- Guidelines recommend lifelong treatment accompanied by diet and exercise interventions
WHO Endorses Expensive Treatment Despite Safety Concerns
The World Health Organization issued guidelines on December 1, 2025, recommending GLP-1 medications for long-term obesity treatment in adults, excluding pregnant women.
The organization’s own admission that this recommendation is “conditional” due to “limited data on their long-term efficacy and safety” raises serious questions about rushing to endorse treatments that could burden healthcare systems worldwide with unprecedented costs.
Today, @WHO published a guideline in JAMA on the use and indications of #GLP1 therapies, including GLP-1 receptor agonists and GLP-1/GIP dual agonists, for the global treatment of #obesity in adults. https://t.co/mgaUmJUUxy 🧵 pic.twitter.com/r90GBm5Ghe
— JAMA (@JAMA_current) December 1, 2025
Massive Market Expansion Driven by American Consumers
The pharmaceutical industry stands to benefit enormously from WHO’s endorsement, with Swiss investment bank UBS projecting the GLP-1 market will surge to $126 billion in sales by 2029. Much of this growth is driven by American consumers, with one in eight adults already reporting taking GLP-1 medications, according to a November 2025 KFF survey. This explosive growth pattern mirrors other healthcare trends where Americans subsidize global pharmaceutical profits.
Global Health Bureaucracy Pushes Lifelong Drug Dependency
WHO Director-General Tedros Adhanom Ghebreyesus promoted the guidelines, which recognize obesity as “a chronic disease that can be treated with comprehensive and lifelong care.”
The emphasis on lifelong treatment creates permanent revenue streams for pharmaceutical companies while potentially making patients dependent on expensive medications. The WHO acknowledges concerns about health inequities and counterfeit products but proceeds with recommendations anyway.
Limited Treatment Options Mask Broader Health Policy Failures
The guidelines specifically cover three GLP-1 medications: liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound).
While the WHO recommends combining these drugs with “structured interventions involving healthy diet and physical activity,” the focus remains on pharmaceutical solutions rather than addressing root causes of obesity.
This approach shifts responsibility from failed public health policies to individual medical treatment, potentially creating massive financial burdens for healthcare systems already strained by government mismanagement.
